News

03/02/2026

Mikrobiomik is set to launch Spain’s first human microbiome therapy in 2026

At Mikrobiomik, we are moving towards a new milestone in microbiome-based medicine. Bilbao,…

07/01/2026

MBK-01 demonstrates its clinical impact against Clostridioides difficile infection

A real-life case shows how a microbiota-based therapy can provide an effective alternative when conventional…

29/07/2025

First patient for phase III trial in decompensated liver cirrhosis

A new milestone achieved: the first patient is recruited for the phase III trial in…

23/07/2025

Mikrobiomik joins the European Microbiome Innovation for Health (EMIH)

We are thrilled to announce that we are part of the European Microbiome Innovation for…

10/07/2025

We have launched a €500,000 round on Capital Cell

10/07/2025 We have launched a €500,000 round on Capital Cell to launch the first oral…

08/04/2025

The future for diverticulitis is already here

The future for diverticulitis is already here. Mikrobiomik recruits the first patient in a trial…

14/02/2025

Good news: EMA approves Paediatric Investigation Plan (PIP) for MBK-01

14/02/2025 Mikrobiomik has reached a new milestone upon receiving the approval of the Paediatric Investigation…

20/01/2025

Global recognition: MBK-01 is the world’s most outstanding healthcare innovation in 2024

20/01/2025 Mikrobiomik Health Company has reached a new milestone by being recognised twice at the…

02/12/2024

The AEMPS authorizes DIREBIOT clinical trial

02/12/2024 Mikrobiomik in association with IRYCIS (Instituto Ramón y Cajal de Investigación Sanitaria) are launching…

02/12/2024

Patricia del Río, new executive director

02/12/2024 Patricia del Río, new executive director: female leadership at the forefront of our mission…

28/11/2024

Mikrobiomik receives its award at the CSIC headquarters in Madrid

28/11/2024 On 28 November 2024, the CSIC hosted the Quality Innovation Awards, QIA 2024 (Spain…

07/11/2024

Winners of the Quality Innovation Award 2024

07/11/2024 The Centers of Excellence announced winners of the Quality Innovation Award (QIA) 2024 -Spain…

29/10/2024

Mikrobiomik celebrates its first Investor’s Day: presents clinical and corporate breakthroughs

29/10/2024 On Thursday 24th October Mikrobiomik celebrated its first INVESTOR'S DAY, a unique meeting, where…

22/10/2024

Mikrobiomik Investors Day

22/10/24 Next Thursday 24th October, Mikrobiomik will hold its first INVERSTORS DAY, which will take…

09/09/2024

A new validation that brings excellence to Mikrobiomik and to the pharmaceutical industry

09/09/24 As a disruptive and pioneering company, Mikrobiomik has achieved a significant milestone by introducing…

23/06/2024

A success story on compassionate use

23/06/2024 “This woman has already benefited from Spanish stool-based pill to kill dangerous bacteria” The…

13/06/2024

The story behind the patients in the ICD-01 clinical trial

13/06/2024 For statistical purposes, a patient is part of the "n" of the clinical trial,…

12/06/2024

AseBio 2023 Report: Milestones and challenges for Spanish Biotech

12/06/2024 AseBio – (Spanish Asociation of biotech companies) presented the AseBio 2023 Report "25 years…

07/06/2024

Mikrobiomik makes impact at BIO2024

07/06/2024 In June, one of the most significant events for biotechnology worldwide companies, the BIO2024…

14/05/2024

“The Economist, special Health”

14/05/2024 An innovation, both in form and substance, is making headway in northern Spain. The…

09/05/2024

Market Access Mentoring for Pymes from AseBio and Alira Health

09/05/2024 Through a selection process, Mikrobiomik has been selected to participate in the Market Access…

29/04/2024

We are launching a strategic investment round together with CaixaBank to launch MBK-01

Mikrobiomik has given CaixaBank CIB the exclusive mandate to assist in the search for potential…

08/03/2024

Celebrating Female Talent at Mikrobiomik

On Friday, March 8th, at Mikrobiomik, we took a moment to honor and celebrate the…

07/03/2024

Scientific Advisory in Santander

On March 11th, took place the Mikrobiomik Scientific Advisory Board, a meeting that we…

18/01/2024

“Stories that Give Life” AseBio campaign

As part of the campaign promoted by AseBio (Spanish Association of Biotechnology Companies) called "Stories…

11/12/2023

Early closure of clinical trial ICD-01

On November 15th of this year, with our CRO "Sermes", we informed to the AEMPS…

26/09/2023

Mikrobiomik closes €1.1 million capital increase

On Wednesday, July 5, Mikrobiomik won the award for Best Idea/Project, after having reached the…

05/07/2023

Winners of the “Toribio Echevarría” for Best Idea/Project Award

On Wednesday, July 5, Mikrobiomik won the award for Best Idea/Project, after having reached the…

04/07/2023

Mikrobiomik chosen by Santander Bank among 1,800 SMEs

On Tuesday July 4th, Mikrobiomik was awarded with the “SME Bizkaia” prize in the category…

17/06/2023

I MIKROSALUD Workshop

The past Saturday June 17th took place in Bilbao the “I MIKROSALUD WORKSHOP”. The event…

16/06/2023

International Biotechnology Day Meeting

On the occasion of the celebration of the International Day of Biotechnology, we met at…

14/06/2023

AseBio annual report

AseBio's annual report 'Deep tech to transform the world'. The annual report on Spanish companies…

26/05/2023

Mikrobiomik showcase at the Pharma Partnering Summit

Mikrobiomik Showcase at the Pharma Partnering Summit in Munich. During the event that took place…

22/05/2023

Mikrobiomik focuses on Europe for 2025

Mikrobiomik seeks up to three million in a round and sets its focus on Europe…

10/05/2023

Mikrobiomik guest at the Congress of Health Logistics

Mikrobiomik special guest at the Congress of Health Logistics in Galicia. On May 9th, we…

28/03/2023

Agreement IRYCIS and Mikrobiomik

IRYCIS and Mikrobiomik sign an agreement for investigations related to the human microbiota. Last…

28/02/2023

Mikrobiomik receives the award “Novel Company”.

On Monday, February 20th, the company was awarded with the "Novel Company" prize. This award…

02/10/2022

Mikrobiomik in the Business section of ABC

“Companies explore the future of the healthcare industry in gut microbiota” The Basque startup Mikrobiomik,…

13/09/2022

Interview on “Nacex” magazine

Interview with Juan Basterra CEO of the company. What is your differential value? The pharmaceutical…

27/07/2022

OSASUNBERRI, a project to support the health industry sector in the Basque Country

Mikrobiomik receives support from the Osasunberri program The official signing of the Basque Government's support…

10/06/2022

Mikrobiomik joins the Board of Directors of the Basque Health Cluster

Mikrobiomik will be part of the new Board of Directors of the Basque Health Cluster…

17/03/2022

Seed Capital Bizkaia takes 3% stake in shares of Mikrobiomik

Seed Capital Bizkaia takes 3% stake in shares of Mikrobiomik. Under its remit to promote…

12/01/2022

Mikrobiomik on television

Mikrobiomik on TV. Last weekend we had the pleasure of appearing on the ETB programme…

04/01/2021

Mikrobiomik receives major grants and subsidies

Since its launch, Mikrobiomik has received grants and subsidies amounting to over €600,000. Thanks to…

11/12/2020

Mikrobiomik, 2020 CEBEK Emprende Prize

Mikrobiomik is a bio-pharmaceutical company headquartered in Derio, near Bilbao (Spain) that belongs to the…

10/12/2020

CEBEK interview with Juan Basterra, CEO of Mikrobiomik

Juan Basterra, CEO of Mikrobiomik, has been interviewed for the CEBEK (Bizkaia Business Confederation) magazine.…

27/06/2019

Mikrobiomik reaches final of CEBEK Emprende awards

Mikrobiomik was shortlisted as a finalist for the 2nd CEBEK Emprende awards, sponsored by the…

09/05/2019

Mikrobiomik moves to BIC Bizkaia

Mikrobiomik moves to new premises at the BIC Bizkaia business incubator. Just a year after…

16/04/2019

Orza invests in Mikrobiomik

ORZA has shown its confidence in Mikrobiomik with a €400,000 investment as part of the…

05/09/2018

Mikrobiomik obtained SME rating from EMA

On 4 July 2018 the European Medicines Agency (EMA) granted an SME rating to Mikrobiomik.…